Skip to main content
padlock icon - secure page this page is secure

Publisher: Nature Publishing

Volume 9, Number 3, 2006

Report from Durham
pp. 199-199(1)
Author: Moul, J. W.

Favourites:
ADD

Prostate News
pp. 201-203(3)

Favourites:
ADD
Favourites:
ADD

Permanent prostate brachytherapy: a century of technical evolution
pp. 215-220(6)
Authors: Acher, P. L.; Morris, S. L.; Popert, R. J.; Perry, M. J.; Potters, L.; Beaney, R. P.

Favourites:
ADD

The changing pattern of management for hormone-refractory, metastatic prostate cancer
pp. 221-229(9)
Authors: James, N. D.; Bloomfield, D.; Luscombe, C.

Favourites:
ADD

Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA levels between 4 and 10 ng/ml
pp. 235-238(4)
Authors: Kaygısız, O.; Uğurlu, O.; Koşan, M.; İnal, G.; Ozturk, B.; Cetinkaya, M.

Favourites:
ADD

The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml
pp. 239-244(6)
Authors: Bastide, C.; Kuefer, R.; Loeffler, M.; de Petriconi, R.; Gschwend, J.; Hautmann, R.

Favourites:
ADD
Favourites:
ADD

Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate
pp. 254-260(7)
Authors: Anscher, M. S.; Clough, R.; Robertson, C. N.; Prosnitz, L. R.; Dahm, P.; Walther, P.; Donatucci, C. F.; Albala, D. M.; Febbo, P.; George, D. J.

Favourites:
ADD

Histopathological findings after radiofrequency (RITA) treatment for prostate cancer
pp. 266-269(4)
Authors: Patriarca, C.; Bergamaschi, F.; Gazzano, G.; Corrada, P.; Ordesi, G.; Zanitzer, L.; Di Pasquale, M.; Giunta, P.; Campo, B.

Favourites:
ADD

The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting
pp. 270-274(5)
Authors: Kastner, C.; Armitage, J.; Kimble, A.; Rawal, J.; Carter, P. G.; Venn, S.

Favourites:
ADD
Favourites:
ADD

Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression
pp. 279-283(5)
Authors: Augustin, H.; Freibauer, C.; Bayer, L.; Lunglmayr, G.; Tschurlovich, F.; Kuber, W.; Pummer, K.

Favourites:
ADD

Germline BCL-2 sequence variants and inherited predisposition to prostate cancer
pp. 284-292(9)
Authors: Kidd, L. R.; Coulibaly, A.; Templeton, T. M.; Chen, W.; Long, L. O.; Mason, T.; Bonilla, C.; Akereyeni, F.; Freeman, V.; Isaacs, W.

Favourites:
ADD

Evidence of a novel biomarker, αs1-Casein, a milk protein, in benign prostate hyperplasia
pp. 293-297(5)
Authors: Xu, K.; Ling, M. T.; Wang, X.; Wong, Y. C.

Favourites:
ADD

Prohibitin mutations are uncommon in prostate cancer families linked to chromosome 17q
pp. 298-302(5)
Authors: White, K. A.; Lange, E. M.; Ray, A. M.; Wojno, K. J.; Cooney, K. A.

Favourites:
ADD

Prostate cancer incidence varies among males from different Y-chromosome lineages
pp. 303-309(7)
Authors: Ewis, A. A.; Lee, J.; Naroda, T.; Sano, T.; Kagawa, S.; Iwamoto, T.; Shinka, T.; Shinohara, Y.; Ishikawa, M.; Baba, Y.

Favourites:
ADD
Favourites:
ADD

Free paper abstracts
pp. 336-363(28)

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more